Straits Times Index
3,314.14 +8.12 (+0.25%) S&P 500
5,463.30 -1.32 (-0.02%) Dow
39,239.68 +89.35 (+0.23%) Nasdaq
17,646.05 -43.31 (-0.24%) Bitcoin USD
61,187.72 -3,063.56 (-4.77%) CMC Crypto 200
1,260.31 -49.41 (-3.77%)
APLS260116C00080000
- Simply Wall St.
Investors might be losing patience for Apellis Pharmaceuticals' (NASDAQ:APLS) increasing losses, as stock sheds 6.3% over the past week
While Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS ) shareholders are probably generally happy, the stock hasn't had...
- Zacks
Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
- GlobeNewswire
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpointData presented at the Clinical Trials at the Summit Meeting WALTHAM, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that SYFOVRE® (pegcetacoplan injection) preserved visual function at 36 months in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). These positive data from the GALE long-term ext
